Strides Pharma Science Ltd has sold a majority stake in its wholly owned subsidiary Pivot Path Pvt Ltd to a consortium led by Ascent Capital and co-investor Vintage Classic for Rs 100 crore, according to a regulatory filing. The company said the board approved the transaction at a meeting held on June 27, 2026.
The deal also includes a primary capital infusion of Rs 50 crore into Pivot Path by Ascent Capital to support the company’s next phase of growth. Strides will receive Rs 75 crore at the initial closing and the remaining Rs 25 crore on the first anniversary of closing.
After the transaction, Strides will retain a 19.95 per cent stake in Pivot Path, while the investor consortium will hold 65.05 per cent and the remaining 15 per cent will be reserved for an employee stock ownership plan pool. In a separate filing, Strides said the deal values Pivot Path at a post-money valuation of Rs 230 crore.
Pivot Path was carved out of Strides’ innovation business through a demerger that became effective earlier this month. The unit contributed around 3 per cent to Strides’ consolidated turnover in FY26.
